St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
- Fundraising
St. Jude Family of Websites
Explore our cutting edge research, world-class patient care, career opportunities and more.
St. Jude Children's Research Hospital Home
- Fundraising
Alberto Pappo, MD
Member, St. Jude Faculty
Co-Leader, Developmental Biology & Solid Tumor Program
Alvin Mauer Endowed Chair
On this page:
Contact Information
Alberto Pappo, MD
Solid Tumor
MS 260, Room C6017
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Education
MD – Medical School, Universidad Anahuac, Mexico City (1984) Residency – The University of Texas Health Science Center, San Antonio, Texas (1985-1988) Fellowship – Children’s Medical Center of Dallas and The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas (1988-1991) Clinical Fellowship – American Cancer Society (1989-1990)
Research Interests
Development of novel therapies for pediatric solid tumors with special interest in:
- Pediatric melanoma
- Soft tissue sarcomas
- Pediatric gastrointestinal stromal tumors
Clinical Trials
Recruiting
Study goal:
Watch patients with low-risk germ cell tumors, after tumor removal, treats their tumor as well as if they got the usual treatment of chemotherapy and/or more surgery if needed.
Recruiting
Study goal:
The purpose of this study is to find out if accelerated chemotherapy will treat germ cell tumors as well as standard. We will also see if both treatments have similar side effects and are well tolerated.
Recruiting
Study goal:
To standardize treatments for all types of pleuropulmonary blastoma and find safer, more effective ways to treat children with this rare lung cancer
Recruiting
Study goal:
Compare the effects of giving less chemotherapy drugs to people with VLR-RMS, who do not have the MYOD1 or TP53 mutation, to find out which is better; to find out how well people with LR-RMS, without MYOD1 or TP53 mutations, respond to standard chemotherapy, and to see the effects of giving chemotherapy drugs for a longer amount of time. We want to see if patients with RMS and the MYOD1 or TP53 mutation benefit from longer therapy than the shorter treatment we give to VLR or LR patients.
Recruiting
Study goal:
To find out whether repotrectinib is safe to use in children and young adults and whether it might work against tumors.
Recruiting
Study goal:
Researchers in this study want to learn more about melanoma tumors in children and adolescents. They want to understand the different types of tumors better and learn how each type responds to treatment. They also want to find out why some children and teens are more likely to develop melanoma. Doctors hope this information will help them decide which melanoma treatments are most effective. They also hope to use this information to develop new treatments for children with melanoma.
Recruiting
Study goal:
To find the most effective treatment for each risk group of rhabdomyosarcoma patients